Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

REPORT: FDA Panel Approves Pfizer COVID-19 Boosters For 65+ And At-Risk Individuals


I recently reported on the FDA Advisory Panel’s vote against boosters of the experimental Pfizer COVID-19 jab for all Americans 16+ years of age.

However, the FDA panel had another vote shortly after.

This vote regarded elderly Americans 65+ years of age and immunocompromised individuals.

Unsurprisingly, the panel gave their stamp of approval here.

While the Biden Administration didn’t get the boosters approved for all adults, I think it’s only a matter of time before they do.

The FDA will make a final decision on Pfizer boosters in the next few days.

And the CDC will also review the booster question next week.

Here’s the latest:

The decision doesn’t surprise me considering some places already offer boosters for immunocompromised.

NYC is one place that already has boosters available.

Here’s the link from my previous article at NYC Health + Hospitals.

It’s only a matter of time before the age drops lower and lower for booster shot availability.

Because the data on the experimental jab’s efficacy is atrocious.

And their solution will be more boosters to increase profits.

Similar to Israel, it will be a cycle of boosters that will never end.

From ABC 3340:

After overwhelmingly rejecting a plan to give Pfizer booster shots against COVID-19 to most Americans, an influential federal advisory panel has approved the extra shots for those who are 65 or older or run a high risk of severe disease.

The twin votes Friday represented a blow to the Biden administration’s sweeping effort to shore up nearly all Americans’ protection amid the spread of the highly contagious delta variant. The decision was made by a committee of outside experts who advise the Food and Drug Administration.

The vote recommending the booster shots for older Americans and other high-risk groups helps salvage part of the White House’s campaign but is still be a huge step back from the sweeping plan proposed by administration a month ago to offer booster shots of both the Pfizer and Moderna vaccines to nearly all Americans eight months after they get their second dose.

During several hours of vigorous debate Friday, members of the panel questioned the value of offering boosters to nearly everyone.

Friday’s vote was just the first step. The FDA itself is expected to make a decision on boosters in the next few days, though it usually follows the committee’s recommendations.

The offering of boosters is also subject to approval by the Centers for Disease Control and Prevention. A CDC advisory panel is expected to take up the question on Wednesday. The CDC has said it is considering boosters for older people, nursing home residents and front-line health care workers, rather than all adults.

Separate FDA and CDC decisions will be needed in order for people who received the Moderna or J&J shots to get boosters.

FOX News also weighed in:

A U.S. Food and Drug Administration (FDA) advisory panel on Friday endorsed emergency approval for the Pfizer-BioNTech COVID-19 vaccine booster shot at least six months following the second dose among people ages 65 and older and those at high risk of occupational exposure and severe COVID-19.

The vote was 18-0. The vote will now go before the FDA to issue a final decision.

The panel earlier Friday afternoon voted to reject licensure of Pfizer’s booster vaccine in people ages 16 and older, at a vote of 2-16.

During the deliberations, panel members suggested older, vulnerable populations may benefit from boosters, but noted insufficient data among younger groups and concerns over potential increased risk for heart inflammation, particularly among males ages 16-17.

The committee was most recently charged with voting whether the safety and effectiveness data from Pfizer’s clinical trial supported emergency use authorization of the company’s booster dose among people 65 years and older and people at high-risk for a severe course of COVID-19 disease.

The meeting included members of the FDA’s Vaccines and Related Biological Products Advisory Committee, (VRBPAC), as well as officials from the Centers for Disease Control and Prevention (CDC), lsrael’s Health Ministry, vaccine experts and Pfizer representatives.

Dr. William Gruber, senior vice president of vaccine clinical research and development at Pfizer, noted Phase 3 trial data indicating waning protection over time, from 96% vaccine efficacy within two months after the second dose to about 84% by six months and amid the dominant delta variant. While protection dropped against infections, it remained effective in preventing hospitalizations.

We know that last sentence is a flat-out lie.

Give it time, they’ll lower the age eligibility for experimental COVID-19 boosters.

But for now, 65+ and immunocompromised will start taking boosters before the end of September.

Unless they say no.


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

Thanks for sharing!